StudyGraphics #VisualAbstract: Durvalumab, trametinib, and dabrafenib triplet therapy may provide robust immunogenicity in patients with BRAF-mutated advanced melanoma January 14, 2021 | Teddy Guo Facebook Twitter Pinterest WhatsApp Linkedin ReddIt Email Print Click to read the study in Nature Communications RELATED ARTICLESMORE FROM AUTHOR #VisualAbstract Asciminib is shown to be safe and efficacious in clinical practice for treating patients with chronic myeloid leukemia #VisualAbstract: Female sex may be associated with better overall and disease-specific survival in Merkel cell carcinoma #VisualAbstract Panobinostat, lenalidomide, bortezomib, and dexamethasone was well-tolerated and showed potential in treating relapsed/refractory multiple myeloma
